OncoMatch/Clinical Trials/NCT06158269
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Is NCT06158269 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies DVRd for multiple myeloma.
Treatment: DVRd — Evaluate the efficacy of DVRd in patients with newly diagnosed double-hit multiple myeloma (MM) and the feasibility of minimal residual disease (MRD) guided maintenance therapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: IGH t(4;14)
At least two high-risk cytogenetic abnormalities: t(4;14), t(14;16), t(14;20), del(17p), gain/amp(1q)
Required: IGH t(14;16)
At least two high-risk cytogenetic abnormalities: t(4;14), t(14;16), t(14;20), del(17p), gain/amp(1q)
Required: IGH t(14;20)
At least two high-risk cytogenetic abnormalities: t(4;14), t(14;16), t(14;20), del(17p), gain/amp(1q)
Required: TP53 deletion (del(17p))
At least two high-risk cytogenetic abnormalities: t(4;14), t(14;16), t(14;20), del(17p), gain/amp(1q)
Required: CKS1B gain/amp(1q)
At least two high-risk cytogenetic abnormalities: t(4;14), t(14;16), t(14;20), del(17p), gain/amp(1q)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: anti-myeloma chemotherapy
Subjects had not received any anti-MM chemotherapy
Cannot have received: extensive pelvic irradiation (more than half of the pelvic area)
extensive pelvic irradiation (more than half of the pelvic area)
Cannot have received: anti-myeloma glucocorticoids
Exception: glucocorticoids for no more than 14 days to control symptoms
anti-MM glucocorticoids, except those who used glucocorticoids for no more than 14 days to control symptoms
Lab requirements
Blood counts
WBC count ≥ 1.5×10^9/L, absolute neutrophil count ≥ 1.0×10^9/L, hemoglobin ≥ 75 g/L, and platelet count ≥ 75×10^9/L (if bone marrow plasmacytes < 50%) or platelet count ≥ 50×10^9/L (if bone marrow plasmacytes ≥ 50%).
Kidney function
Creatinine clearance rate ≥ 30 mL/min (calculated by cockcroft and Gault formulas).
Liver function
Total bilirubin < 1.5 × ULN (total bilirubin in patients with Gilbert's syndrome can be restricted to <3 × ULN), and AST and ALT ≤ 2.5 × ULN.
Total bilirubin < 1.5 × ULN (total bilirubin in patients with Gilbert's syndrome can be restricted to <3 × ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN. Creatinine clearance rate ≥ 30 mL/min (calculated by cockcroft and Gault formulas). Routine blood test within 7 days before the first day of cycle 1 meets the following criteria: white blood cell (WBC) count ≥ 1.5×10^9/L, absolute neutrophil count ≥ 1.0×10^9/L, hemoglobin ≥ 75 g/L, and platelet count ≥ 75×10^9/L (if bone marrow plasmacytes < 50%) or platelet count ≥ 50×10^9/L (if bone marrow plasmacytes ≥ 50%).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06158269 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require IGH?
Yes, IGH t(4;14) is a required biomarker for enrollment.
Does this trial require IGH?
Yes, IGH t(14;16) is a required biomarker for enrollment.
Does this trial require IGH?
Yes, IGH t(14;20) is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages